Mast cells: Pivotal players in cardiovascular diseases

Current Cardiology Reviews

Volumn 4, Issue 3, 2008, Pages 170-178

  Bot, Ilze ^a   van Berkel, Theo J C ^a   Biessen, Erik A L ^a,b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Aneurysm; Atherosclerosis; Cardiovascular diseases; Mast cell; Plaque stability; Proteases

Indexed keywords

EID: 54749132591     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340308785160624     Document Type: Review

References (113)

1. Ehrlich P. Beiträge zur theorie und praxis der histologischen färbung. Thesis, Leipzig University. 1878.
2. Ehrlich P. Beiträge zur Kenntniss der Anilinfärbungen und ihrer Verwendung in der mikroskopischen Technik. Arch Mikr Anat 1877; 13: 263.
3. Vyas H, Krishnaswamy G. Paul Ehrlich's "Mastzellen" - from aniline dyes to DNA chip arrays: a historical review of developments in mast cell research. Methods Mol Biol 2006; 315: 3-11.
4. Kelly JL, Chi DS, Abou-Auda W, Smith JK, Krishnaswamy G. The molecular role of mast cells in atherosclerotic cardiovascular disease. Mol Med Today 2000; 6: 304-8.
5. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005; 23: 749-86.
6. Krishnaswamy G, Ajitawi O, Chi DS. The human mast cell: an overview. Methods Mol Biol 2006; 315: 13-34.
7. Lusis AJ. Atherosclerosis. Nature 2000; 407:233-41.
8. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
9. Shukla SA, Veerappan R, Whittimore JS, Ellen Miller L, Youngberg GA. Mast cell ultrastructure and staining in tissue. Methods Mol Biol 2006; 315: 63-76.
10. Nakano, T, Sonoda T, Hayashi C, et al. Fate of bone marrow-derived cultured mast cells after intracutaneous, intraperitoneal, and intravenous transfer into genetically mast cell-deficient W/Wv mice. Evidence that cultured mast cells can give rise to both connective tissue type and mucosal mast cells. J Exp Med 1985; 162:1025-43.
11. Bienenstock J, Befus AD, Pearce F, Denburg J, Goodacre R. Mast cell heterogeneity: derivation and function, with emphasis on the intestine. J Allergy Clin Immunol 1982; 70: 407-12.
12. Plump AS, Smith JD, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-53.
13. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468-71.
14. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92: 883-93.
15. van den Maagdenberg AM, Hofker MH, Krimpenfort PJ, et al. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem 1993; 268: 10540-5.
16. Michael LH, Entman ML, Hartley CJ, et al. Myocardial ischemia and reperfusion: a murine model. Am J Physiol 1995; 269: H2147-54.
17. Chimenti S, Carlo E, Masson S, Bai A, Latini R. Myocardial infarction: animal models. Methods Mol Med 2004; 98: 217-26.
18. Anidjar S, Salzmann JL, Gentric D, Lagneau P, Camilleri JP, Michel JB. Elastase-induced experimental aneurysms in rats. Circulation 1990; 82: 973-81.
19. Gertz SD, Kurgan A, Eisenberg D. Aneurysm of the rabbit common carotid artery induced by periarterial application of calcium chloride in vivo. J Clin Invest 1988; 81: 649-56.
20. Morimoto M, Miyamoto S, Mizoguchi A, Kume N, Kita T, Hashimoto N. Mouse model of cerebral aneurysm: experimental induction by renal hypertension and local hemodynamic changes. Stroke 2002; 33: 1911-5.
21. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105: 1605-12.
22. Kitamura Y, Go S, Hatanaka K. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 1978; 52: 447-52.
23. Kitamura Y, Go S. Decreased production of mast cells in S1/S1d anemic mice. Blood 1979; 53: 492-7.
24. Galli SJ, Kitamura Y. Genetically mast-cell-deficient W/Wv and Sl/Sld mice. Their value for the analysis of the roles of mast cells in biologic responses in vivo. Am J Pathol 1987; 127: 191-98.
25. Niwa Y, Kasugai T, Ohno K, et al. Anemia and mast cell depletion in mutant rats that are homozygous at "white spotting (Ws)" locus. Blood 1991; 78: 1936-41.
26. Grimbaldeston MA, Chen CC, Piliponsky AM, Tsai M, Tam SY, Galli SJ. Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol 2005; 167: 835-48.
27. Kraneveld AD, Buckley TL, van Heuven-Nolsen D, van Schaik Y, Koster AS, Nijkamp FP. Delayed-type hypersensitivity-induced increase in vascular permeability in the mouse small intestine: inhibition by depletion of sensory neuropeptides and NK1 receptor blockade. Br J Pharmacol 1995; 114: 1483-89.
28. Hessel EM, van Oosterhout AJM, Hofstra CL, et al. Bronchoconstriction and airway hyperresponsiveness after ovalbumin inhalation in sensitized mice. Eur J Pharmacol 1995; 293: 401-12.
29. Mousli M, Hugli TE, Landry Y, Bronner C. Peptidergic pathway in human skin and rat peritoneal mast cell activation. Immunopharmacology 1994; 27: 1-11.
30. Constantinides P. Mast cells and susceptibility to experimental atherosclerosis. Science 1953; 117:505-6.
31. Cairns A, Constantinides P. Mast cells in human atherosclerosis. Science 1954; 120:31-2.
32. Atkinson JB, Harlan CW, Harlan GC, Virmani R. The association of mast cells and atherosclerosis: a morphologic study of early atherosclerotic lesions in young people. Hum Pathol 1994; 25: 154-9.
33. Forman MB, Oates JA, Robertson D, Robertson RM, Roberts LJ 2nd, Virmani R. Increased adventitial mast cells in a patient with coronary spasm. N Engl J Med 1985; 313: 1138-41
34. Takai S, Shiota N, Jin D, Miyazaki M. Functional role of chymase in angiotensin II formation in human vascular tissue. J Cardiovasc Pharmacol 1998; 32: 826-33.
35. Richard V, Hurel-Merle S, Scalbert E, et al. Functional evidence for a role of vascular chymase in the production of angiotensin II in isolated human arteries. Circulation 2001; 104: 750-52.
36. Nakano A, Kishi F, Minami K, Wakabayashi H, Nakaya Y, Kido H. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J Immunol 1997; 159: 1987-92.
37. Maguire JJ, Kuc RE, Davenport AP. Vasoconstrictor activity of novel endothelin peptide, ET-1(1 - 31), in human mammary and coronary arteries in vitro. Br J Pharmacol 2001; 134: 1360-6.
38. Lindstedt KA, Kokkonen JO, Kovanen PT. Inhibition of coppermediated oxidation of LDL by rat serosal mast cells. A novel cellular protective mechanism involving proteolysis of the substrate under oxidative stress. Arterioscler Thromb 1993; 13: 23-32.
39. Lindstedt KA. Inhibition of macrophage-mediated low density lipoprotein oxidation by stimulated rat serosal mast cells. J Biol Chem 1993; 268: 7741-6.
40. Paananen K, Kovanen PT. Proteolysis and fusion of low density lipoprotein particles independently strengthen their binding to exocytosed mast cell granules. J Biol Chem 1994; 269: 2023-31.
41. Kaartinen M, Penttilä A, Kovanen PT. Extracellular mast cell granules carry apolipoprotein B-100-containing lipoproteins into phagocytes in human arterial intima. Functional coupling of exocytosis and phagocytosis in neighbouring cells. Arterioscler Thromb Vasc Biol 1995; 15: 2047-54.
42. Lee M, Calabresi L, Chiesa G, Franceschini G, Kovanen PT. Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2002; 22: 1475-81.
43. Liao L, Granger DN. Role of mast cells in oxidized low-density lipoprotein-induced microvascular dysfunction. Am J Physiol 1996; 271: H1795-800.
44. Liao L, Starzyk RM, Granger DN. Molecular determinants of oxidized low-density lipoprotein-induced leukocyte adhesion and microvascular dysfunction. Arterioscler Thromb Vasc Biol 1997; 17: 437-44.
45. Kinoshita M, Okada M, Hara M, Furukawa Y, Matsumori A. Mast cell tryptase in mast cell granules enhances MCP-1 and interleukin-8 production in human endothelial cells. Arterioscler Thromb Vasc Biol 2005; 25: 1858-63.
46. Haley KJ, Lilly CM, Yang JH, et al. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation 2000; 102: 2185-9.
47. Jeziorska M, McCollum C, Woolley DE. Mast cell distribution, activation, and phenotype in atherosclerotic lesions of human carotid arteries. J Pathol 1997; 182: 115-22.
48. Jeziorska M, McCollum C, Woolley DE. Calcification in atherosclerotic plaque of human carotid arteries: associations with mast cells and macrophages. J Pathol 1998; 185: 10-7.
49. Kaartinen M, Penttilä A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 1994; 90: 1669-78.
50. Kaartinen M, Penttilä A, Kovanen PT. Mast cells of two types differing in neutral protease composition in the human aortic intima. Demonstration of tryptase- and tryptase/chymase-containing mast cells in normal intimas, fatty streaks, and the shoulder region of atheromas. Arterioscler Thromb 1994; 14: 966-72.
51. Okayama Y. Mast cell matrix interactions. Clin Exp Allergy 2000; 30: 455-7.
52. Oki T, Kitaura J, Eto K, et al. Integrin alphaIIbbeta3 induces the adhesion and activation of mast cells through interaction with fibrinogen. J Immunol 2006; 176: 52-60.
53. Krüger-Krasagakes S, Grützkau A, Krasagakis K, Hoffmann S, Henz BM. Adhesion of human mast cells to extracellular matrix provides a co-stimulatory signal for cytokine production. Immunology 1999; 98: 253-7.
54. Lees M, Taylor DJ, Woolley DE. Mast cell proteinases activate precursor of collagenase and stromelysin but not of gelatinases A and B. Eur J Biochem 1994; 223: 171-77.
55. Gruber BL, Marchese MJ, Suzuki K, et al. Synovial procollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activation. J Clin Invest 1989; 84: 1657-62.
56. Johnson JL, Jackson CL, Angelini GD, George SJ. Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 1998; 18: 1707-15.
57. Laine P, Kaartinen M, Pentillä A, Panula P, Paavonen T, Kovanen PT. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation 1999; 99: 361-69.
58. Laine P, Naukkarinen A, Heikkilä L, Pentillä A, Kovanen PT. Adventitial mast cells connect with sensory nerve fibers in atherosclerotic coronary segments. Circulation 2000; 101: 1665-69.
59. Chaldakov GN, Stankulov IS, Fiore M, Ghenev PI, Aloe L. Nerve growth factor levels and mast cell distribution in human coronary atherosclerosis. Atherosclerosis 2001; 159: 57-66.
60. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 1995; 92: 1084-8.
61. Mäyränpää MI, Heikkilä HM, Lindstedt KA, Walls AF, Kovanen PT. Desquamation of human coronary artery endothelium by human mast cell proteases: implications for plaque erosion. Coron Artery Dis 2006; 17: 611-21.
62. Ihara M, Urata H, Kinoshita A, et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999;33:1399-405.
63. Hara M, Matsumori A, Ono K, et al. Mast cells cause apoptosis of cardiomyocytes and proliferation of other intramyocardial cells in vitro. Circulation 1999; 100: 1443-49.
64. Leskinen MJ, Wang Y, Leszczynski D, Lindstedt KA, Kovanen PT. Mast cell chymase induces apoptosis of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001; 21: 516-22.
65. Leskinen MJ, Heikkila HM, Speer MY, et al. Mast cell chymase induces smooth muscle cell apoptosis by disrupting NF-kappaB-mediated survival signaling. Exp Cell Res 2006; 312: 1289-98.
66. Leskinen MJ, Lindstedt KA, Wang Y, Kovanen PT. Mast cell chymase induces smooth muscle cell apoptosis by a mechanism involving fibronectin degradation and disruption of focal adhesions. Arterioscler Thromb Vasc Biol 2003; 23: 238-43.
67. Lätti S, Leskinen M, Shiota N, Wang Y, Kovanen PT, Lindstedt KA. Mast cell-mediated apoptosis of endothelial cells in vitro: a paracrine mechanism involving TNF-alpha-mediated downregulation of bcl-2 expression. J Cell Physiol 2003; 195: 130-38.
68. Heikkilä HM, Lätti S, Leskinen MJ, Hakala JK, Kovanen PT, Lindstedt KA. Activated mast cells induce endothelial cell apoptosis by a combined action of chymase and tumor necrosis factor-alpha. Arterioscler Thromb Vasc Biol 2008; 28: 309-14.
69. -/- mice after adenovirus-mediated transfer of p53. Circulation 2002; 105: 2064-70.
70. Bennett MR. Apoptosis in the cardiovascular system. Heart 2002; 87: 480-87.
71. Kaartinen M, Pentillä A, Kovanen PT. Mast cells accompany microvessels in human coronary atheromas: implications for intimal neovascularization and hemorrhage. Atherosclerosis 1996; 123: 123-31.
72. Boesiger J, Tsai M, Maurer M, et al. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of fc epsilon receptor I expression. J Exp Med 1998; 188: 1135-45.
73. Lappalainen H, Laine P, Pentikäinen MO, Sajantila A, Kovanen PT. Mast cells in neovascularized human coronary plaques store and secrete basic fibroblast growth factor, a potent angiogenic mediator. Arterioscler Thromb Vasc Biol 2004; 24: 1880-85.
74. Sun J, Sukhova GK, Wolters PJ, et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 2007; 13: 719-24.
75. von der Thusen JH, van Berkel TJC, Biessen EAL. Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Circulation 2001; 103:1164-70.
76. Bot I, de Jager SC, Zernecke A, et al. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation 2007; 115: 2516-25.
77. Chen HY, Sharma BB, Yu L. Role of galectin-3 in mast cell functions: galectin-3-deficient mast cells exhibit impaired mediator release and defective JNK expression. J Immunol 2006; 177: 4991-7.
78. Nachtigal M, Ghaffar A, Mayer EP. Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am J Pathol 2008; 172: 247-55.
79. Chaldakov GN, Fiore M, Stankulov IS, et al. NGF, BDNF, leptin, and mast cells in human coronary atherosclerosis and metabolic syndrome. Arch Physiol Biochem 2001; 109: 357-60.
80. Moriyama M, Sato T, Inoue H, et al. The neuropeptide neuromedin U promotes inflammation by direct activation of mast cells. J Exp Med 2005; 202: 217-24.
81. Ferry X, Brehin S, Kamel R, Landry Y. G protein-dependent activation of mast cell by peptides and basic secretagogues. Peptides 2002; 23: 1507-15.
82. Huang M, Pang X, Letourneau R, Boucher W, Theoharides TC. Acute stress induces cardiac mast cell activation and histamine release, effects that are increased in Apolipoprotein E knockout mice. Cardiovasc Res 2002; 55: 150-60.
83. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis: histological and immunohistochemical studies. Circulation 1994; 90: 844-53.
84. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low-density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 1999; 19: 1218-22.
85. Veinot JP, Prichett-Pejic W, Song J, et al. CD117-positive cells and mast cells in adult human cardiac valves - observations and implications for the creation of bioengineered grafts. Cardiovasc Pathol 2006; 15: 36-40.
86. Helske S, Lindstedt KA, Laine M, et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 2004; 44: 1859-66.
87. Helske S, Syväranta S, Kupari M, et al. Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves. Eur Heart J 2006; 27: 1495-1504.
88. Korkmaz ME, Oto A, Saraçlar Y, et al. Levels of IgE in the serum of patients with coronary arterial disease. Int J Cardiol 1991; 31: 199-204.
89. Clejan S, Japa S, Clemetson C, Hasabnis SS, David O, Talano JV. Blood histamine is associated with coronary artery disease, cardiac events and severity of inflammation and atherosclerosis. J Cell Mol Med 2002; 6: 583-92.
90. van Haelst PL, Timmer JR, Crijns HJ, Kauffman HF, Gans RO, van Doormaal JJ. No long-lasting or intermittent mast cell activation in acute coronary syndromes. Int J Cardiol 2001; 78: 75-80.
91. Kervinen H, Kaartinen M, Mäkynen H, Palosuo T, Mänttäri M, Kovanen PT. Serum tryptase levels in acute coronary syndromes. Int J Cardiol 2005; 104: 138-43.
92. Filipiak KJ, Tarchalska-Krynska B, Opolski G, et al. Tryptase levels in patients after acute coronary syndromes: the potential new marker of an unstable plaque? Clin Cardiol 2003; 26: 366-72.
93. Deliargyris EN, Upadhya B, Sane DC, et al. Mast cell tryptase: a new biomarker in patients with stable coronary artery disease. Atherosclerosis 2005; 178:381-6.
94. Masini E, Giannella E, Bianchi S, Mannaioni PF. Histamine and lactate dehydrogenase (LDH) release in ischemic myocardium of the guinea-pig. Agents Actions 1987; 20: 281-3.
95. Engels W, Reiters PH, Daemen MJ, Smits JF, van der Vusse GJ. Transmural changes in mast cell density in rat heart after infarct induction in vivo. J Pathol 1995; 177: 423-9.
96. Frangogiannis NG, Perrard JL, Mendoza LH, et al. Stem cell factor induction is associated with mast cell accumulation after canine myocardial ischemia and reperfusion. Circulation 1998; 98: 687-98.
97. Jin D, Takai S, Yamada M, Sakaguchi M, Yao Y, Miyazaki M. Possible roles of cardiac chymase after myocardial infarction in hamster hearts. Jpn J Pharmacol 2001; 86: 203-14.
98. Jin D, Takai S, Yamada M, Sakaguchi M, Miyazaki M. Beneficial effects of cardiac chymase inhibition during the acute phase of myocardial infarction. Life Sci 2002; 71: 437-46.
99. Hoshino F, Urata H, Inoue Y, et al. Chymase inhibitor improves survival in hamsters with myocardial infarction. J Cardiovasc Pharmacol 2003; 41 Suppl 1: S11-8.
100. Jin D, Takai S, Yamada M, et al. Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc Res 2003; 60: 413-20.
101. Zhang QY, Ge JB, Chen JZ, et al. Mast cell contributes to cardiomyocyte apoptosis after coronary microembolization. J Histochem Cytochem 2006; 54: 515-23.
102. Thompson RW. Basic science of abdominal aortic aneurysms: emerging therapeutic strategies for an unresolved clinical problem. Curr Opin Cardiol 1996; 11: 504-18.
103. Faleiro LC, Machado CR, Gripp A Jr, Resende RA, Rodrigues PA. Cerebral vasospasm: presence of mast cells in human cerebral arteries after aneurysm rupture. J Neurosurg 1981; 54: 733-5.
104. Saunders SL, Ford SE. Primary coronary artery dissection possibly related to drug hypersensitivity in a male. Can J Cardiol 1991; 7: 138-40.
105. Nishimoto M, Takai S, Fukumoto H, et al. Increased local angiotensin II formation in aneurysmal aorta. Life Sci 2002; 71: 2195-205.
106. Tsunemi K, Takai S, Nishimoto M, et al. Possible roles of angiotensin II-forming enzymes, angiotensin converting enzyme and chymase-like enzyme, in the human aneurysmal aorta. Hypertens Res 2002; 25: 817-22
107. Ejiri J, Inoue N, Tsukube T, et al. Oxidative stress in the pathogenesis of thoracic aortic aneurysm: protective role of statin and angiotensin II type 1 receptor blocker. Cardiovasc Res 2003; 59: 988-96.
108. Furubayashi K, Takai S, Jin D, et al. Chymase activates promatrix metalloproteinase-9 in human abdominal aortic aneurysm. Clin Chim Acta 2008; 388: 214-6.
109. Tsuruda T, Kato J, Hatakeyama K, et al. Adrenomedullin in mast cells of abdominal aortic aneurysm. Cardiovasc Res 2006; 70: 158-64.
110. Tsunemi K, Takai S, Nishimoto M, et al. A specific chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N- 3,4-dioxo-1-phenyl-7-(2-pyridyloxy)]-2-heptyl]acetamide (NK3201), suppresses development of abdominal aortic aneurysm in hamsters. J Pharmacol Exp Ther 2004; 309: 879-83.
111. Furubayashi K, Takai S, Jin D, et al. The significance of chymase in the progression of abdominal aortic aneurysms in dogs. Hypertens Res 2007; 30: 349-57.
112. Sun J, Sukhova GK, Yang M, et al. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest 2007; 117: 3359-68.
113. Tsuruda T, Kato J, Hatakeyama K, et al. Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res 2008; [Epub ahead of print].